Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71–93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study / Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L.. - In: LEUKEMIA. - ISSN 0887-6924. - STAMPA. - (2021), pp. 1121-1133. [10.1038/s41375-020-01018-y]

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Vannucchi A. M.;Sordi B.;Morettini A.;Nozzoli C.;Poggesi L.;Pieralli F.;Bartoloni A.;Atanasio A.;Miselli F.;Paoli C.;Loscocco G. G.;Fanelli A.;Para O.;Berni A.;Tassinari I.;Zammarchi L.;Maggi L.;Mazzoni A.;Scotti V.;Falchetti G.;Malandrino D.;Millotti G.;Bencini S.;Capone M.;Piccinni M. P.;Annunziato F.;Guglielmelli P.;Mannelli F.;Coltro G.;Fantoni D.;Borella M.;Ravenda E.;Peruzzi B.;Caporale R.;Cosmi L.;Liotta F.;Lombardelli L.;Logiodice F.;Vanni A.;Salvati L.;Bonizzoli M.;Peris A.;Cianchi G.;Bosi A.;Pucatti M.;Fontanari P.;Benemei S.;MatucciCerinic M.;
2021

Abstract

Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71–93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.
2021
1121
1133
Goal 3: Good health and well-being for people
Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A...espandi
File in questo prodotto:
File Dimensione Formato  
41375_2020_Article_1018.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.85 MB
Formato Adobe PDF
1.85 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1204796
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 52
social impact